Kenneth Sooi
Overview
Explore the profile of Kenneth Sooi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
23
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chong W, Low J, Tay J, Le T, Goh G, Sooi K, et al.
Lancet Oncol
. 2025 Jan;
26(2):175-186.
PMID: 39826567
Background: Vascular endothelial growth factor (VEGF) is overexpressed in nasopharyngeal carcinoma and suppresses the anti-tumour immune response. Previous studies have shown that adding anti-VEGF treatment to PD-1 inhibition treatment strategies...
2.
Lee J, Huang Y, Oya Y, Nutzinger J, LE Ang Y, Sooi K, et al.
Lung Cancer
. 2024 Jul;
194:107862.
PMID: 38959670
Despite the efficacy of immunotherapy in non-small cell lung cancer (NSCLC), the majority of the patients experience relapse with limited subsequent treatment options. Preclinical studies of various epithelial tumors, such...
3.
Sooi K, Walsh R, Kumarakulasinghe N, Wong A, Ngoi N
Cancer Drug Resist
. 2023 Oct;
6(3):656-673.
PMID: 37842236
Immunotherapy has become integral in cancer therapeutics over the past two decades and is now part of standard-of-care treatment in multiple cancer types. While various biomarkers and pathway alterations such...
4.
Low J, Huang Y, Sooi K, Chan Z, Yong W, Lee S, et al.
Front Oncol
. 2022 Dec;
12:932212.
PMID: 36465401
The rising cost of oncological drugs poses a global challenge to patients, insurers, and policy makers, with the leading drugs worldwide by revenue from immune checkpoint inhibitors (ICIs). Despite its...
5.
Loh J, Wijaya S, Sooi K, Chia P, Soo R
Transl Lung Cancer Res
. 2022 Aug;
11(7):1241-1246.
PMID: 35958327
No abstract available.
6.
Low J, Huang Y, Sooi K, Ang Y, Chan Z, Spencer K, et al.
Int J Cancer
. 2021 Feb;
149(1):169-176.
PMID: 33634869
A dose of 200 mg 3-weekly of pembrolizumab was approved by the Food and Drug Administration (FDA) as treatment for advanced non-small cell lung cancer (NSCLC) without oncogenic drivers. This...